Pharma Focus Asia

MaSTherCell SA Announces New Manufacturing Facility in Belgium


MaSTherCell SA announced new manufacturing facility in Belgium for cell and gene therapy products.


The company has signed a lease agreement for a 5,700m2 (61,354ft²) facility located in Belgium.

The new facility will become a state-of-the-art manufacturing and production site designed for late-stage and commercially approved cell and gene therapy products.

This new site will significantly expand MaSTherCell’s current European manufacturing capacity.

MaSTherCell will continue to use its existing site for both industrialisation and early to mid-stage clinical programs.

In addition, the facility will be included with industry 4.0 precepts such as software integration, intelligent equipment and integrated processes with the objective to provide cell and gene therapy community.

The manufacturing facility is expected to be operational in early 2021.

This state-of-the-art plant will create several hundred jobs and Belgian expertise needs to train the teams.


NameMaSTherCell SA
TypeNew Construction
Parties InvolvedMaSTherCell SA
ScheduleScheduled to be operational in 2021
Latest Issue
Get instant
access to our latest e-book
MFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Gibco Adherent Kidney Media PanelCPHI Korea 2024Equinix accelerated medical research...CHEMICAL INDONESIA 2024Thermofisher - Antibody Therapeutic PolishingINALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024
Searching for an end-to-end patient tech solution?